MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
MicroRNAs comprise a broad class of small non-coding RNAs that control expression of complementary target messenger RNAs. Dysregulation of microRNAs by several mechanisms has been described in various disease states including cardiac disease. Whereas previous studies of cardiac disease have focused on microRNAs that are primarily expressed in cardiomyocytes, the role of microRNAs expressed in other cell types of the heart is unclear. Here we show that microRNA-21 (miR-21, also known as Mirn21) regulates the ERK-MAP kinase signalling pathway in cardiac fibroblasts, which has impacts on global cardiac structure and function. miR-21 levels are increased selectively in fibroblasts of the failing heart, augmenting ERK-MAP kinase activity through inhibition of sprouty homologue 1 (Spry1). This mechanism regulates fibroblast survival and growth factor secretion, apparently controlling the extent of interstitial fibrosis and cardiac hypertrophy. In vivo silencing of miR-21 by a specific antagomir in a mouse pressure-overload-induced disease model reduces cardiac ERK-MAP kinase activity, inhibits interstitial fibrosis and attenuates cardiac dysfunction. These findings reveal that microRNAs can contribute to myocardial disease by an effect in cardiac fibroblasts. Our results validate miR-21 as a disease target in heart failure and establish the therapeutic efficacy of microRNA therapeutic intervention in a cardiovascular disease setting.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Epigenetic manipulation through long non-coding RNAs, miRNA modulators, and other oligonucleotides has yielded promising outcomes in experimental settings.162–165”
From Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis (2020) · cites this paper as [162]
Citations
Cites
1 retracted
Rockman, H. A., Ross, R. S., Harris, A. N., Knowlton, K. U., Steinhelper, M. E., Field, L. J., Ross, J., & Chien, K. R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.18.8277 · Cited by 797
RetractedBartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
The functions of animal microRNAs
Ambros, V. (2004) · Nature · doi:10.1038/nature02871 · Cited by 10,728
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
Self-citationA microRNA component of the p53 tumour suppressor network
He, L., He, X., Lim, L. P., de Stanchina, E., Xuan, Z., Liang, Y., Xue, W., Zender, L., Magnus, J., Ridzon, D., et al. (2007) · Nature · doi:10.1038/nature05939 · Cited by 2,692
A synthetic inhibitor of the mitogen-activated protein kinase cascade.
Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J., & Saltiel, A. R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.17.7686 · Cited by 2,679
MicroRNA-133 controls cardiac hypertrophy
Carè, A., Catalucci, D., Felicetti, F., Bonci, D., Addario, A., Gallo, P., Bang, M.-L., Segnalini, P., Gu, Y., Dalton, N. D., et al. (2007) · Nature Medicine · doi:10.1038/nm1582 · Cited by 1,776
Control of Stress-Dependent Cardiac Growth and Gene Expression by a MicroRNA
van Rooij, E., Sutherland, L. B., Qi, X., Richardson, J. A., Hill, J., & Olson, E. N. (2007) · Science · doi:10.1126/science.1139089 · Cited by 1,657
Dysregulation of Cardiogenesis, Cardiac Conduction, and Cell Cycle in Mice Lacking miRNA-1-2
Zhao, Y., Ransom, J. F., Li, A., Vedantham, V., von Drehle, M., Muth, A. N., Tsuchihashi, T., McManus, M. T., Schwartz, R. J., & Srivastava, D. (2007) · Cell · doi:10.1016/j.cell.2007.03.030 · Cited by 1,429
Yang, B., Lin, H., Xiao, J., Lu, Y., Luo, X., Li, B., Zhang, Y., Xu, C., Bai, Y., Wang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1569 · Cited by 1,138
Cited by
Items 401–500 of 1,006
Noncoding RNA in age-related cardiovascular diseases
Greco, S., Gorospe, M., & Martelli, F. (2015) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2015.01.011 · Cited by 120
“Fibrotic myocardium also shows high levels of miR-21; by lowering the abundance of target protein SPRY2, miR-21 activates signaling through ERK/MAPK, leading to increased fibrosis and decreased apoptosis [70].”
BackgroundLimana, F., Esposito, G., D’Arcangelo, D., Carlo, A. D., Romani, S., Melillo, G., Mangoni, A., Bertolami, C., Pompilio, G., Germani, A., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019845 · Cited by 120
“and miR-133b exhibited only a non-significant diminution both in the infarct and in the border zone [18–22] (Figure S5).”
BackgroundIntermolecular Interactions of Sprouty Proteins and Their Implications in Development and Disease
Edwin, F., Anderson, K. M., Ying, C., & Patel, T. B. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.055848 · Cited by 129
“Another recent report has also shown that miR21 levels are increased in fibroblasts derived from failing hearts (Thum et al., 2008).”
BackgroundmiR-193 expression differentiates telocytes from other stromal cells
Cismasiu, V. B., Radu, E., & Popescu, L. M. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01325.x · Cited by 116
“miR-21 is also detected in cardiac fibroblasts, with levels selectively increased in interstitial fibrosis and cardiac hypertrophy [19].”
BackgroundMicroRNA 10a Marks Regulatory T Cells
Jeker, L. T., Zhou, X., Gershberg, K., de Kouchkovsky, D. A., Morar, M. M., Stadthagen, G., Lund, A. H., & Bluestone, J. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036684 · Cited by 122
“Of note, similar discrepancies between pharmacological miRNA inhibition and genetic ablation have been described for another miRNA and other pharmacologic inhibitors [13,25].”
BackgroundmiR-21 in ischemia/reperfusion injury: a double-edged sword?
Xu, X., Kriegel, A. J., Jiao, X., Liu, H., Bai, X., Olson, J., Liang, M., & Ding, X. (2014) · Physiological Genomics · doi:10.1152/physiolgenomics.00020.2014 · Cited by 114
“In addition to the PTEN/Akt pathway, Sprouty homolog 1 (Spry1), a miR-21 target gene, in the ERK-MAPK signaling pathway is also involved in cardiac fibrosis.”
InfluentialCardiac Hypertrophy Is Positively Regulated by MicroRNA miR-23a
Wang, K., Lin, Z.-Q., Long, B., Li, J.-H., Zhou, J., & Li, P.-F. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.266940 · Cited by 113
Xu, C., Hu, Y., Hou, L., Ju, J., Li, X., Du, N., Guan, X., Liu, Z., Zhang, T., Qin, W., et al. (2014) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2014.07.009 · Cited by 113
MicroRNA Deregulations in Head and Neck Squamous Cell Carcinomas
Chen, D., Cabay, R. J., Jin, Y., Wang, A., Lu, Y., Shah-Khan, M., & Zhou, X. C. (2013) · Journal of Oral and Maxillofacial Research · doi:10.5037/jomr.2013.4102 · Cited by 121
“, PTEN [41], PDCD4 [40], Tropomyosin [46], Sprouty 1 and 2 [47,48], Bcl2 [49], RECK [50], JAG1 [51], HNRPK [46], TGFBRII [52], P12/CDK2AP1 [53], MEF2C [54], RhoB [55] and hMSH2 [56]), which supports the role of miR-21 as an oncomiR.”
BackgroundMasci, P. G., Doulaptsis, C., Bertella, E., Torto, A. D., Symons, R., Pontone, G., Barison, A., Droogné, W., Andreini, D., Lorenzoni, V., et al. (2014) · Circulation Heart Failure · doi:10.1161/circheartfailure.113.000996 · Cited by 116
“Hypertension, n (%) 67 (29) 15 (25) 52 (31) 0.”
InfluentialPAI-1–regulated miR-21 defines a novel age-associated fibrogenic pathway in muscular dystrophy
Ardite, E., Perdiguero, E., Vidal, B., Gutarra, S., Serrano, A. L., & Muñoz‐Cánoves, P. (2012) · The Journal of Cell Biology · doi:10.1083/jcb.201105013 · Cited by 122
“…in most tumor types analyzed so far, miR-21 is considered an oncomiR (Medina et al., 2010; Pan et al., 2011), although it has also been detected in heart and lung cells after tissue damage (Thum et al., 2008; Liu et al., 2010), suggesting physiopathological functions besides cancer promotion.”
InfluentialA phenotypic screen to identify hypertrophy-modulating microRNAs in primary cardiomyocytes
Jentzsch, C., Leierseder, S., Loyer, X., Flohrschütz, I., Sassi, Y., Hartmann, D., Thum, T., Laggerbauer, B., & Engelhardt, S. H. (2011) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2011.07.010 · Cited by 123
Self-citationHromadníková, I., Kotlabová, K., Hympanova, L. H., & Krofta, L. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.11.032 · Cited by 126
“We focus mainly on thosemicroRNAs playing a role in pathogenesis of dyslipidemia [21,22], hypertension [23–25], vascular inflammation [26,27], insulin resistance and diabetes [28], atherosclerosis [29,30], angiogenesis [31,32], coronary artery disease [24,27,31,33], myocardial infarction and heart failure [23,34–37].”
BackgroundFunction and Therapeutic Potential of Noncoding RNAs in Cardiac Fibrosis
Creemers, E. E., & van Rooij, E. (2015) · Circulation Research · doi:10.1161/circresaha.115.305242 · Cited by 118
Huang, Z., Chen, X., Qian, C., Dong, Q., Ding, D., Wu, Q., Li, J., Wang, H., Li, W., Xie, Q., et al. (2016) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.115.003396 · Cited by 118
Electrochemical Detection of MicroRNAs via Gap Hybridization Assay
Pöhlmann, C., & Sprinzl, M. (2010) · Analytical Chemistry · doi:10.1021/ac100186p · Cited by 117
MicroRNA Sequence Profiles of Human Kidney Allografts With or Without Tubulointerstitial Fibrosis
Ben‐Dov, I. Z., Muthukumar, T., Morozov, P. S., Mueller, F. B., Tuschl, T., & Suthanthiran, M. (2012) · Transplantation · doi:10.1097/tp.0b013e3182751efd · Cited by 122
“MiR-21 antagonists administered for the treatment of cardiac fibrosis in pressure-overloaded mice inhibited interstitial fibrosis and improved cardiac function (34).”
BackgroundSelf-citationToldo, S. A., Das, A., Mezzaroma, E., Chau, V. Q., Marchetti, C., Durrant, D., Samidurai, A., Tassell, B. W. V., Yin, C., Ockaili, R. A., et al. (2014) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.113.000381 · Cited by 121
“Moreover, in vivo systemic delivery of antagomiR-21 reduced extracellularregulated kinase–mitogen-activated protein kinase activity, inhibited interstitial fibrosis, and attenuated cardiac dysfunction.(51) However, a more recent study in miR-21 knockout mice revealed that stress-dependent adverse cardiac remodeling de…”
BackgroundThe prognostic value of circulating microRNAs in heart failure
Çakmak, H. A., Coşkunpınar, E. M., İkitimur, B., Barman, H. A., Karadağ, B., Tiryakioğlu, N. O., Kahraman, K., & Vural, V. A. (2015) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000233 · Cited by 111
Cardiac Fibrosis: Cellular Effectors, Molecular Pathways, and Exosomal Roles
Jiang, W., Xiong, Y., Li, X., & Yang, Y. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.715258 · Cited by 127
“It has been confirmed that miR-21 played an essential role in fibroblast biology and that the levels were selectively increased in the failing heart, which makes it a target in heart failure (146).”
BackgroundSeizer, P., Ochmann, C., Schönberger, T., Zach, S., Rose, M., Borst, O., Klingel, K., Kandolf, R., MacDonald, H. R., Nowak, R. A., et al. (2011) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.225771 · Cited by 118
Self-citationDong, S., Ma, W., Hao, B., Hu, F., Yan, L., Yan, X., Wang, Y., Chen, Z., & Wang, Z. (2014) · Europe PMC (PubMed Central) · Cited by 127
Fix, L. N., Shah, M., Efferth, T., Farwell, M. A., & Zhang, B. (2010) · PubMed · Cited by 124
Park, S. J., Cheon, E. J., Lee, M. H., & Kim, H. A. (2013) · Arthritis & Rheumatism · doi:10.1002/art.38188 · Cited by 123
microRNA Therapeutics in Cardiovascular Disease Models
Dangwal, S., & Thum, T. (2013) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135957 · Cited by 114
Self-citationPan, Z., Zhao, W., Zhang, X., Wang, B., Wang, J., Sun, X., Liu, X., Feng, S., Yang, B., & Lu, Y. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01070.x · Cited by 107
“The augmentation of extracellular signal-regulated kinase (ERK1/2) activity caused by the up-regulation of miR-21 enhances CF proliferation and thereby the interstitial fibrosis and cardiac dysfunction (Thum et al., 2008).”
BackgroundInfluentialCirculating and urinary micro RNA profile in focal segmental glomerulosclerosis: a pilot study
Ramezani, A., Devaney, J. M., Cohen, S. D., Wing, M. R., Scott, R., Knoblach, S. M., Singhal, R., Howard, L., Kopp, J. B., & Raj, D. S. (2015) · European Journal of Clinical Investigation · doi:10.1111/eci.12420 · Cited by 113
Targeting Myocardial Remodelling to Develop Novel Therapies for Heart Failure
Tarone, G., Balligand, J., Bauersachs, J. K., Clerk, A., Windt, L. J. D., Heymans, S. R. B., Hilfiker‐Kleiner, D., Hirsch, E., Iaccarino, G., Knöll, R., et al. (2014) · European Journal of Heart Failure · doi:10.1002/ejhf.62 · Cited by 114
Self-citationMicroRNAs and atrial fibrillation: new fundamentals
Wang, Z., Lu, Y., & Yang, B. (2010) · Cardiovascular Research · doi:10.1093/cvr/cvq350 · Cited by 115
Ning, Z.-W., Luo, X.-Y., Wang, G.-Z., Li, Y., Pan, M.-X., Yang, R.-Q., Ling, X.-G., Huang, S., Ma, X.-X., Jin, S.-Y., et al. (2017) · Antioxidants & Redox Signaling · doi:10.1089/ars.2016.6669 · Cited by 106
“MicroRNA-21 (mir-21) has been shown to promote fibrogenesis in cardiac muscle (38), kidneys (46), and lungs Innovation”
MicroRNA-21 in the pathogenesis of acute kidney injury
Li, Y., Jing, Y., Hao, J., Frankfort, N. C., Zhou, X., Shen, B., Liu, X., Wang, L., & Li, R. (2013) · Protein & Cell · doi:10.1007/s13238-013-3085-y · Cited by 113
“MiR-21 down-regulated apoptosis and necrosis of renal TECs, which promoted cellular proliferation and played a protective role in the response to stress and infl ammation in renal IRI (Lindsay, 2008; Thum et al., 2008a; Godwin et al., 2010).”
BackgroundMicroRNAs as potential targets for progressive pulmonary fibrosis
Rajasekaran, S., Rajaguru, P., & Paramasivam, S. G. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00254 · Cited by 127
Comparison of different miR-21 inhibitor chemistries in a cardiac disease model
Thum, T., Chau, N., Bhat, B., Gupta, S. K., Linsley, P. S., Bauersachs, J., & Engelhardt, S. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45938 · Cited by 107
Self-citationPotential Clinical Implications of miR-1 and miR-21 in Heart Disease and Cardioprotection
Kura, B., Kalocayova, B., Devaux, Y., & Bartekova, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030700 · Cited by 106
“On the other hand, miR-21 can protect cardiomyocytes against hypertrophy and apoptosis [97,122].”
BackgroundInfluentialClinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer
Rachagani, S., Macha, M. A., Heimann, N., Seshacharyulu, P., Haridas, D., Chugh, S., & Batra, S. K. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.10.020 · Cited by 110
“Similarly, cardiac fibrosis and hypertrophy was significantly reduced after targeting miR-21 and mir-133 respectively [240,241].”
Zhao, J., Tang, N., Wu, K., Dai, W., Ye, C., Shi, J., Zhang, J., Ning, B., Zeng, X., & Lin, Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108005 · Cited by 105
“miR-21, which has been shown to promote fibrogenic activation of fibroblasts [20,35] and to be implicated in the amplification of a series of important cellular signaling pathways [21,36,37].”
BackgroundCorreia, A. C. P., Moonen, J.-R. A. J., Brinker, M. G. L., & Krenning, G. (2016) · Journal of Cell Science · doi:10.1242/jcs.176248 · Cited by 106
MicroRNAs and the resolution phase of inflammation in macrophages
Alam, M. M., & O'Neill, L. A. (2011) · European Journal of Immunology · doi:10.1002/eji.201141740 · Cited by 109
Roderburg, C., Mollnow, T., Bongaerts, B. W. C., Elfimova, N., Cardenas, D. V., Janssen, K., Zimmermann, H. W., Koch, A. H., Vucur, M., Luedde, M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032999 · Cited by 114
“Since miRNAs control networks of target genes and are thus promising therapeutic targets, such findings are of high potential for the establishment of miRNA-based antifibrotic therapies, which have already been tested in other organs like the heart [13].”
BackgroundLi, T., Wu, R., Zhang, Y., & Zhu, D. (2011) · BMC Genomics · doi:10.1186/1471-2164-12-186 · Cited by 122
“86 [19,39,86]”
Ruggeri, C., Gioffré, S., Achilli, F., Colombo, G. I., & D’Alessandra, Y. (2018) · Heart Failure Reviews · doi:10.1007/s10741-017-9653-0 · Cited by 104
“This choice was driven by the known activation of this miRNA in cardiovascular diseases, including myocardial infarction and cardiac fibrosis [40, 41], and by its anti-apoptotic function in ischemia/reperfusion- and hypoxia/re-oxygenation-induced cardiomyocyte apoptosis [42].”
BackgroundRole of MicroRNAs in TGF-β Signaling Pathway-Mediated Pulmonary Fibrosis
Kang, H. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122527 · Cited by 112
Leifheit-Nestler, M., Kirchhoff, F., Nespor, J., Richter, B., Soetje, B., Klintschar, M., Heineke, J., & Haffner, D. (2018) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy006 · Cited by 103
MicroRNA-155 Promotes Atherosclerosis Inflammation via Targeting SOCS1
Yang, Y., Yang, L., Liang, X., & Zhu, G. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000430303 · Cited by 106
Song, C., Zhang, J., Liu, Y., Pan, H., Qi, H., Cao, Y., Zhao, J., Li, S., Guo, J., Sun, H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7312 · Cited by 105
“In a pressure-overload-induced disease model reduced cardiac ERK-MAP kinase activity, inhibited interstitial fibrosis and attenuated cardiac dysfunction [16].”
BackgroundA Deep Sequencing Approach to Uncover the miRNOME in the Human Heart
Leptidis, S., el Azzouzi, H., Lok, S. I., de Weger, R., Olieslagers, S., Kisters, N., Silva, G. J., Heymans, S., Cuppen, E., Berezikov, E., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057800 · Cited by 101
“In fact, while many miRNAs which regulation has been considered a signature of heart failure (miR-133a, miR-1, miR-21, miR-214, miR-212, miR-29, miR129, miR199a) [18,43–51], were confirmed by deep sequencing to be differentially regulated in HCM, only a few could be confirmed using this technique in DCM (miR-214, miR-…”
MicroRNA-21: a therapeutic target for reversing drug resistance in cancer
Hong, L., Han, Y., Zhang, Y., Zhang, H., Zhao, Q., Wu, K., & Fan, D. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.819853 · Cited by 110
“The following direct targets have been experimentally validated: reversion-inducing cysteine-rich protein with kazal motifs [67], LRRFIPI [68], Tap63 [69], HNRPK [69], PDCD4 [70], PTEN [71], tropomyosin 1 [72], ras homolog gene family and member B [73], sprouty homolog 1/2 [74], Fas ligand [75], Cdc25a [76], B-cell tr…”
BackgroundMicroRNAs in the cardiovascular system
Han, M., Toli, J., & Abdellatif, M. (2011) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e328345983d · Cited by 111
Role of microRNA in diabetic cardiomyopathy: From mechanism to intervention
Guo, R., & Nair, S. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.03.013 · Cited by 99
“Among the miRNAs miR-21 [60], miR-320 [61], miR-141 [62], miR-30d [58], miR-34a [63], miR-301a [64], miR-451 [65], miR-206, miR-223 [66, 67], miR-483-3p [68], miR-216a, miR-221 [69], miR-195 [70], miR-199a-3p, miR-700, miR-142-3p, miR-24, miR-499-3p, miR-208a and miR-705 [71] have often been found to be upregulated, w…”
MicroRNA-221-3p, a TWIST2 target, promotes cervical cancer metastasis by directly targeting THBS2
Wei, W.-F., Zhou, C.-F., Wu, X., He, L.-N., Wu, L.-F., Chen, X., Yan, R.-M., Zhong, M., Yu, Y., Liang, L., et al. (2017) · Cell Death and Disease · doi:10.1038/s41419-017-0077-5 · Cited by 103
Retractedde Gonzalo‐Calvo, D., Vea, À., Bär, C., Fiedler, J., Couch, L. S., Brotons, C., Llorente‐Cortés, V., & Thum, T. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy234 · Cited by 109
“Accordingly, the manipulation of ncRNA expression has emerged as a novel and promising therapeutic approach.(23,24) Of note, clinical tri-”
BackgroundSelf-citationKang, H., Davis‐Dusenbery, B. N., Nguyen, P. H., Lal, A., Lieberman, J., Aelst, L. V., Lagna, G., & Hata, A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.303156 · Cited by 106
The IGF1-PI3K-Akt Signaling Pathway in Mediating Exercise-Induced Cardiac Hypertrophy and Protection
Weeks, K. L., Bernardo, B. C., Ooi, J. Y. Y., Patterson, N. L., & McMullen, J. R. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-4304-8_12 · Cited by 117
Nersisyan, S. A., Shkurnikov, M. Y., Turchinovich, A. A., Knyazev, E. N., & Tonevitsky, A. (2020) · PLoS ONE · doi:10.1371/journal.pone.0235987 · Cited by 104
“Furthermore, multiple reports have consistently shown that aberrant miRNA expression is associated with various pathologies including cancer [12–14], neurological [15, 16] and cardiovascular diseases [17, 18].”
BackgroundMiR-21 Protected Cardiomyocytes against Doxorubicin-Induced Apoptosis by Targeting BTG2
Tong, Z., Jiang, B., Wu, Y., Liu, Y., Li, Y., Gao, M., Jiang, Y., Lv, Q., & Xiao, X. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160714511 · Cited by 106
“Its expression has been found to be activated not only in multiple types of cancers, such as breast, liver, brain, and prostatmyometrial cancers [10], but also in cardiovascular diseases including myocardial infarction and cardiac fibrosis [11,12].”
BackgroundMiR‐320a contributes to atherogenesis by augmenting multiple risk factors and down‐regulating SRF
Chen, C., Wang, Y., Yang, S., Li, H., Zhao, G., Wang, F. Y., Yang, L., & Wang, D. W. (2015) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12483 · Cited by 108
“Recently several miRNAs have been implicated in cardiac pathology such as cardiac hypertrophy [4], arrhythmia [5], fibrosis [6], ischemia/reperfusion [7] and vascular diseases such as post-angioplasty restenosis [8] and angiogenesis [9].”
BackgroundSex- and estrogen-dependent regulation of a miRNA network in the healthy and hypertrophied heart
Queirós, A. M., Eschen, C., Fliegner, D., Kararigas, G., Dworatzek, E., Westphal, C., Sanchez‐Ruderisch, H., & Regitz‐Zagrosek, V. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.09.002 · Cited by 112
“MiR-21 acts by modulating the MAPK-ERK1/2 pathway through inhibition of Srpy1 [21].”
BackgroundInfluentialFernandes, T. M., Soci, Ú. P. R., & de Oliveira, E. M. (2011) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2011007500112 · Cited by 125
“Reports have suggested that an miR-21 antagomir might be therapeutically useful in preventing heart failure in mice, although genetic deletion of miR-21 did not confer a dysfunctional phenotype, suggesting possible confounding factors that may be a product of technical variations, miR redundancy or nonspecific effects…”
BackgroundGambari, R., Fabbri, E., Borgatti, M., Lampronti, I., Finotti, A., Brognara, E., Bianchi, N., Manicardi, A., Marchelli, R., & Corradini, R. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.08.007 · Cited by 115
microRNAs in the onset and development of cardiovascular disease
Vickers, K. C., Rye, K., & Tabet, F. (2013) · Clinical Science · doi:10.1042/cs20130203 · Cited by 107
microRNA in Cardiovascular Aging and Age-Related Cardiovascular Diseases
de Lucia, C., Komici, K., Borghetti, G., Femminella, G. D., Bencivenga, L., Cannavò, A., Corbi, G., Ferrara, N., Houser, S. R., Koch, W. J., et al. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00074 · Cited by 114
“Cardiac miR-21 shows a profibrotic role in both HF and aging heart while miR-22 exercises a pro-hypertrophy effect in HF and accelerates fibroblast migration during cardiac aging (51, 52, 110, 125).”
BackgroundInfluentialLi, X., Wei, Y., & Wang, Z. (2018) · Hypertension Research · doi:10.1038/s41440-018-0071-z · Cited by 112
Hulshoff, M. S., Xu, X., Krenning, G., & Zeisberg, E. M. (2018) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.118.311276 · Cited by 101
miRNA therapeutics in cardiovascular diseases: promises and problems
Nouraee, N., & Mowla, S. J. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00232 · Cited by 99
“These latter cells release the second subset of exosomes that lead to myocardial regeneration or protection (Sahoo and Losordo, 2014).”
BackgroundBarana, A., Matamoros, M., Dolz-Gaitón, P., Pérez-Hernández, M., Amorós, I., Núñez, M., Sacristán, S., Pedraz, Á., Pinto, Á. G., Fernández‐Avilés, F., et al. (2014) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.114.001709 · Cited by 111
“was attributed to its presence in fibroblasts that affects cardiac myocytes in a paracrine fashion.(14) In human atria, miR-21 was found in whole atrial biopsies.”
BackgroundBlood-based microRNA signatures differentiate various forms of cardiac hypertrophy
Derda, A. A., Thum, S., Lorenzen, J. M., Bavendiek, U., Heineke, J., Keyser, B., Stuhrmann, M., Givens, R. C., Kennel, P. J., Christian Schulze, P., et al. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.05.185 · Cited by 101
Self-citationmicroRNAs in cardiovascular development
Chen, J., & Wang, D. (2012) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2012.01.012 · Cited by 110
“Knockdown of miR-21 by an antagomir was shown to prevent cardiac hypertrophy and fibrosis in response to pressure overload [70].”
Li, X., Zhu, L., Wang, B., Yuan, M., & Zhu, R. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00855 · Cited by 108
“Among them, miR-21 induces extracellular-signal regulated kinase/MAPK activity via the inhibition of Spry1 to protect cardiac fibroblasts survival (Thum et al., 2008).”
BackgroundFrom traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases
Landmesser, U., Poller, W., Tsimikas, S., Most, P., Paneni, F., & Lüscher, T. F. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa229 · Cited by 99
A general fragment-based approach to identify and optimize bioactive ligands targeting RNA
Suresh, B. M., Li, W., Zhang, P., Wang, K. W., Yildirim, I., Parker, C. G., & Disney, M. D. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2012217117 · Cited by 106
“We applied this strategy to develop a potent and selective bioactive ligand targeting the precursor to microRNA-21 (pre-miR-21), a ncRNA linked to cancers (25) and other indications (26 – 28) (Fig.”
Zhang, J., Jiao, J., Cermelli, S., Muir, K., Jung, K. H., Zou, R., Rashid, A., Gagea, M., Zabludoff, S., Kalluri, R., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-1254 · Cited by 106
“A role for miR-21 in renal and cardiac fibrosis has been previously reported (1, 12, 35).”
MicroRNAs and Diabetic Complications
Natarajan, R., Putta, S., & Kato, M. (2012) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-012-9368-5 · Cited by 99
Chuppa, S., Liang, M., Liu, P., Liu, Y., Casati, M. C., Cowley, A. W., Patullo, L., & Kriegel, A. J. (2018) · Kidney International · doi:10.1016/j.kint.2017.05.014 · Cited by 99
miR-21 mediates nickel nanoparticle-induced pulmonary injury and fibrosis
Mo, Y., Zhang, Y., Wan, R., Jiang, M., Xu, Y., & Zhang, Q. (2020) · Nanotoxicology · doi:10.1080/17435390.2020.1808727 · Cited by 101
“Notably, previous studies showed that exposure to particles, such as diesel exhaust particles and particulate matter, caused upregulation of miR-21 (Bollati et al. 2010; Zhou et al. 2015). miR-21 was reported to contribute to pulmonary and cardiac fibrosis by repressing Spry1 and PTEN (Bronnum et al. 2013; Thum et al.…”
BackgroundInfluentialThe Role of microRNAs in Metabolic Syndrome-Related Oxidative Stress
Włodarski, A., Strycharz, J., Wróblewski, A. M., Kasznicki, J., Drzewoski, J., & Śliwińska, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186902 · Cited by 107
Jakubik, D., Fitas, A., Eyileten, C., Jarosz-Popek, J., Nowak, A., Czajka, P., Wicik, Z., Sourij, H., Siller-Matula, J. M., Rosa, S. D., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01245-2 · Cited by 105
MicroRNAs in Cardiovascular Biology and Heart Disease
Catalucci, D., Gallo, P., & Condorelli, G. (2009) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.109.857425 · Cited by 107
Non-cardiomyocyte microRNAs in heart failure
Tijsen, A. J., Pinto, Y. M., & Creemers, E. E. (2012) · Cardiovascular Research · doi:10.1093/cvr/cvr344 · Cited by 89
“There are various reports which indicate that when growth of the microvasculature does not keep pace with the extent of cardiomyocyte hypertrophy, myocardial hypoxia will cause myocardial dysfunction.44 This was illustrated in a model of pressure overload-induced hypertrophy, where blockade of VEGF reduced capillary d…”
BackgroundInfluentialSala, L. L., Mrakic‐Sposta, S., Micheloni, S., Prattichizzo, F., & Ceriello, A. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0748-2 · Cited by 105
Atrial fibrosis underlying atrial fibrillation (Review)
Li, C., Zhang, J., Hu, W., & Li, S. (2020) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2020.4842 · Cited by 118
“Studies have shown that miR‐21 can target sprouty homolog 1, an ERK inhibitor, which acti‐ vates the ERK/MAPK signalling pathway to promote cardiac fibroblast proliferation and fibrogenesis (77,78).”
BackgroundSharma, S., Liu, J., Wei, J., Yuan, H., Zhang, T., & Bishopric, N. H. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201200234 · Cited by 108
“…and function, as well as in cardiac disorders in humans and animal models (Callis et al, 2009; Care et al, 2007; Cheng et al, 2007; Dong et al, 2010; Landthaler et al, 2004; Sayed et al, 2007; Tatsuguchi et al, 2007; Thum et al, 2007, 2008; van Rooij et al, 2006, 2007; Zhao et al, 2007).”
Shen, E., Diao, X., Wang, X., Chen, R., & Hu, B. Q. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.04.034 · Cited by 101
MiRNA inhibition in tissue engineering and regenerative medicine
Beavers, K. R., Nelson, C. E., & Duvall, C. L. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.12.006 · Cited by 108
The role of microRNAs in skin fibrosis
Babalola, O., Mamalis, A., Lev‐Tov, H. A., & Jagdeo, J. R. (2013) · Archives of Dermatological Research · doi:10.1007/s00403-013-1410-1 · Cited by 101
MicroRNAs and Cardiac Regeneration
Hodgkinson, C. P., Kang, M. H., Dal-Pra, S., Mirotsou, M., & Dzau, V. J. (2015) · Circulation Research · doi:10.1161/circresaha.116.304377 · Cited by 104
“AntagomiRs, miRNAs modified with cholesterol or phosphorothioate moieties to increase their stability in vivo,(140) have been used to reduce the expression of miRNAs that mediate pathology after myocardial injury.(144) AntagomiRs may also prove to be a useful ally for cardiac reprogramming.”
MicroRNAs: Regulating a Change of Heart
Barringhaus, K. G., & Zamore, P. D. (2009) · Circulation · doi:10.1161/circulationaha.107.715839 · Cited by 105
MicroRNA identity and abundance in porcine skeletal muscles determined by deep sequencing
Nielsen, M. M., Hansen, J., Hedegaard, J., Nielsen, R. O., Panitz, F., Bendixen, C., & Thomsen, B. (2010) · Animal Genetics · doi:10.1111/j.1365-2052.2009.01981.x · Cited by 104
Small Things Matter: Relevance of MicroRNAs in Cardiovascular Disease
Peters, L. J. F., Biessen, E. A. L., Hohl, M., Weber, C., van der Vorst, E. P. C., & Santovito, D. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00793 · Cited by 105
Small non-coding RNA therapeutics for cardiovascular disease
Shah, A. M., & Giacca, M. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac463 · Cited by 100
miRNA screening reveals a new miRNA family stimulating iPS cell generation via regulation of Meox2
Pfaff, N., Fiedler, J., Holzmann, A., Schambach, A., Moritz, T., Cantz, T., & Thum, T. (2011) · EMBO Reports · doi:10.1038/embor.2011.176 · Cited by 96
“In the context of reprogramming, the interference of Meox2 with TGF-b signalling might be of particular importance (Valcourt et al, 2007), as suppression of TGF-b signalling is a key mechanism in iPSC generation (Ichida et al, 2009).”
BackgroundSelf-citationCirculating and Urinary microRNAs in Kidney Disease
Lorenzen, J. M., & Thum, T. (2012) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01170212 · Cited by 102
“Several animal studies have shown that the in vivo use of specific miRNA antagonists is an effective treatment option in various diseases (41,42).”
BackgroundSelf-citationA review of currently identified small molecule modulators of microRNA function
Meter, E. N. V., Onyango, J. A., & Teske, K. A. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.112008 · Cited by 103
Early biomarkers of doxorubicin-induced heart injury in a mouse model
Desai, V. G., Kwekel, J. C., Vijay, V., Moland, C. L., Herman, E. H., Lee, T., Han, T., Lewis, S. M., Davis, K. J., Muskhelishvili, L., et al. (2014) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2014.10.006 · Cited by 100
Santulli, G. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-22380-3_4 · Cited by 98
Liang, L., Stone, R. C., Stojadinović, O., Ramirez, H. A., Pastar, I., Maione, A. G., Smith, A., Yanez, V., Veves, A., Kirsner, R. S., et al. (2016) · Wound Repair and Regeneration · doi:10.1111/wrr.12470 · Cited by 103
“It has been reported that miR-21-5p suppresses RECK and SPRY1 expression by direct targeting 30-UTR.(15,19) RECK is a membrane-anchored glycoprotein, which negatively regulates MMPs(26,27) and modulate cell-ECM interaction.”
BackgroundAre targeted therapies for diabetic cardiomyopathy on the horizon?
Tate, M., Grieve, D., & Ritchie, R. H. (2017) · Clinical Science · doi:10.1042/cs20160491 · Cited by 104
MicroRNAs in cardiomyocyte development
Malizia, A. P., & Wang, D. (2010) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.111 · Cited by 109
A MicroRNA Guide for Clinicians and Basic Scientists: Background and Experimental Techniques
Bernardo, B. C., Charchar, F. J., Lin, R. C. Y., & McMullen, J. R. (2011) · Heart Lung and Circulation · doi:10.1016/j.hlc.2011.11.002 · Cited by 115
Banjo, T., Grajcarek, J., Yoshino, D., Osada, H., Miyasaka, K. Y., Kida, Y. S., Ueki, Y., NAGAYAMA, K., Kawakami, K., MATSUMOTΟ, T., et al. (2013) · Nature Communications · doi:10.1038/ncomms2978 · Cited by 109
Yang, T., Liang, Y., Lin, Q., Liu, J., Luo, F., Li, X., Zhou, H., Zhuang, S., & Zhang, H. (2013) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24474 · Cited by 96
“Increasing evidences showed that miRNAs are key regulators of genes involved in fibrosis in organs, such as heart [Thum et al., 2008; Van Rooij et al., 2008], kidney [Chung et al., 2010], and liver [Chu and Friedman, 2008].”
BackgroundResult
Metadata
- Authors
- Thum, T., Gross, C., Fiedler, J., Fischer, T., Kissler, S., Bussen, M., Galuppo, P., Just, S., Rottbauer, W., Frantz, S., Castoldi, M., Soutschek, J., Koteliansky, V., Rosenwald, A., Basson, M. A., Licht, J. D., Pena, J. T. R., Rouhanifard, S. H., Muckenthaler, M. U., Tuschl, T., Martin, G. R., Bauersachs, J., & Engelhardt, S.
- Affiliations
- University of Würzburg (DE)
- Deutsche Forschungsgemeinschaft (DE)
- University of California, San Francisco (US)
- Heidelberg University (DE)
- Regulus Therapeutics (United States) (US)
- Alnylam Pharmaceuticals (United States) (US)
- King's College London (GB)
- Northwestern University (US)
- Rockefeller University (US)
- Technical University of Munich (DE)
- Corresponding author
- Bauersachs, Johann
- Engelhardt, Stefan
- ORCID
- Thum, Thomas
- Gross, Carina
- Fiedler, Jan
- Fischer, Thomas
- Kissler, Stephan
- Galuppo, Paolo
- Just, Steffen
- Rottbauer, Wolfgang
- Frantz, Stefan
- Castoldi, Mirco
- Rosenwald, Andreas
- Basson, M. Albert
- Licht, Jonathan D.
- Pena, John T. R.
- Rouhanifard, Sara H.
- Muckenthaler, Martina U.
- Tuschl, Thomas
- Bauersachs, Johann
- Engelhardt, Stefan
- Venue
- Nature
- Published
- 2008-11-30
- Volume
- 456
- Issue
- 7224
- Pages
- 980-984
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2132093971
- Cited by
- 2,349
- References
- 30
- Citations by year
- 2026: 62 · 2025: 70 · 2024: 71 · 2023: 76 · 2022: 106 · 2021: 131 · 2020: 151 · 2019: 138 · 2018: 153 · 2017: 167 · 2016: 150 · 2015: 200 · 2014: 183 · 2013: 203 · 2012: 176
- FWCI
- 75.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Funders
- National Cancer Institute (R01CA078711, R01 CA 78711, R01CA059998)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Congenital heart defects research
- Keywords
- miR-21, cardiac fibroblasts, heart failure, SPRY1, interstitial fibrosis, cardiac hypertrophy, microRNA silencing, antagomir, fibroblast survival, therapeutic target, cardiomyocytes
- MeSH terms
- Animals, Cell Line, Cell Survival, Cells, Cultured, Disease Models, Animal, Fibroblasts, Humans, Male, Mice, Transgenic, Cardiomyopathies, Gene Silencing, MAP Kinase Signaling System, Myocytes, Cardiac, MicroRNAs, Extracellular Signal-Regulated MAP Kinases, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.